New Preeclampsia Treatment Offers Hope

A new treatment for severe early preeclampsia is showing promise in a pilot trial, offering a potential way to safely extend pregnancy for mothers at risk of premature birth. Researchers at Cedars-Sinai Health Sciences University found that filtering a protein called sFlt-1 from the blood of pregnant women with preeclampsia both reduced blood pressure and appeared to be safe, according to a study led by Ravi Thadhani.

Preeclampsia, characterized by high blood pressure and protein in the urine, affects approximately one in twelve pregnancies in the United States. Currently, the only cure for preeclampsia is delivery of the baby, which often leads to premature birth and associated complications for both mother and child. This new research offers a potential alternative to managing the condition and prolonging gestation.

Blood Filtering Shows Modest Blood Pressure Reduction

The pilot trial involved 16 women experiencing preterm preeclampsia. Researchers discovered that removing sFlt-1 through blood filtration resulted in a modest reduction in blood pressure among the participants. While the study is preliminary, the findings are encouraging and suggest a targeted treatment approach may be possible.

“We’re excited about this. [It’s the] first time anyone has developed a targeted treatment for this condition,”

Ravi Thadhani, executive vice president of clinical affairs and chief medical officer at the Cedars-Sinai Medical Center and Cedars-Sinai Health System

The research team emphasizes that further investigation is needed to confirm these results and determine the long-term effects of sFlt-1 filtration. However, the initial findings represent a significant step forward in the search for effective preeclampsia treatments.

Understanding Preeclampsia and Current Treatment Limitations

Preeclampsia remains a life-threatening condition during pregnancy, and its exact causes are not fully understood. Existing treatments primarily focus on managing symptoms and preventing severe complications until delivery is necessary. The lack of a targeted therapy has long been a challenge for clinicians and researchers.

The Medical College of Wisconsin (MCW) is also conducting a clinical trial, supported by a grant from the Gates Foundation, to investigate another potential treatment for preeclampsia. This trial is examining whether the supplement MitoQ can improve vascular function in patients with the condition, potentially leading to longer and healthier pregnancies. Jennifer McIntosh, associate professor of obstetrics and gynecology at MCW, noted the current limitations in treatment options.

“There is currently no medication that can cure preeclampsia or really even hold it at bay,”

Jennifer McIntosh, associate professor of obstetrics and gynecology at MCW

McIntosh explained that currently, the only definitive treatment is delivery, which can result in the newborn requiring intensive care. The MCW trial aims to address vascular dysfunction, a key component believed to contribute to preeclampsia.

While the Cedars-Sinai study focuses on filtering sFlt-1, and the MCW trial investigates MitoQ, both approaches represent innovative efforts to address the underlying mechanisms of preeclampsia and improve outcomes for pregnant women and their babies. The need for effective treatments is underscored by the fact that preeclampsia affects up to 8 percent of pregnant women worldwide.

The Cedars-Sinai research builds on established blood filtering techniques used for conditions like kidney disease, adapting the technology for a targeted approach to preeclampsia. The initial success of this pilot trial provides a foundation for larger, more comprehensive studies to evaluate the efficacy and safety of sFlt-1 filtration on a broader scale.

Further research will be crucial to determine the optimal timing, dosage, and patient selection criteria for this new treatment. However, the preliminary results offer a hopeful outlook for women at risk of preeclampsia and the potential for improved pregnancy outcomes.